Nektar Therapeutics (NKTR) Misses Q1 EPS by 7c, Revenues Beat
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $75.92 --0%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
EGRX, MOVE, MDRX, More
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
EGRX, MOVE, MDRX, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.78), $0.07 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $50.57 million versus the consensus estimate of $47.64 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c
- RCM Technologies (RCMT) Tops Q2 EPS by 17c
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
